Építés alatt – nem éles oldal
Belépés
LeállítvaFázis nélkül

ThRombosis ExclUsion STudy

A legfontosabb adatok

Ki végzi
Diagnostica Stago
Hol
Allentown, Bethlehem, Boston, Campbellsville, Chicago, Columbus, Dallas, Durham, Indianapolis, New Haven, Philadelphia és St Louis (Egyesült Államok)Mind a 12 helyszín megnézéseMég 4 másik országban, 8 helyszínen
Azonosító
Állapot
Leállítva
Résztvevők
5935 fő vett részt
Kezdés
2018. jún. 25.
Befejezés
2024. szept. 5.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • DDimer test
A regiszteradat frissítve
2025. február 25.
Miért állt le
Due to the unstability of samples included in the plasmabank using the reference method: VIDAS system, Stago decided to not use the plasmabank to assess the pre-specified primary objective. Therefore, this study was halted prematurely.

Ki vehet részt

Életkor
Legfeljebb 79 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Patient is < 80 years old
  • Patient presents at least one of these symptoms indicative of proximal DVT or PE:; symptoms for proximal DVT: leg pain, tenderness (discomfort through palpation), leg swelling, and /or edema,; symptoms for PE: hemoptysis, lung related chest pain, dyspnea
  • Patient provides written informed consent to participate in the study
  • Patient is willing to comply with specified follow-up evaluation at 3 months and can be contacted by telephone

Ki nem vehet részt

  • Patient presenting with a condition that may be associated with increased D-dimer levels, even in the absence of VTE, such as:; Fibrinolytic therapy within the previous seven (7) days,; Disseminated intravascular coagulation; Bone fracture or surgery (with general anesthesia longer than thirty (30) minutes) within the previous one (1) month,; Deep hematoma diagnosed by imaging techniques within the previous one (1) month,; Disseminated malignancies and active cancer (active cancer defined as: cancer for which therapeutic or palliative treatment is either ongoing at the time of enrolment or has stopped less than six (6) months before enrolment),; Sepsis, severe infections, pneumonia within the previous 1 month,; Known liver cirrhosis,; Pregnancy or having delivered within the previous 1 month,; Atherosclerotic vascular disease thrombosis within the previous 1month (e.g. myocardial infarction, stroke, coronary syndrome, peripheral artery disease stage III or IV),; Sickle cell disease,
  • Patients with previous DVT/PE occurred less than three (3) months from screening
  • Major co-morbid condition(s) or other reasons that could limit the patient's ability to participate in the study or to comply with follow-up requirements, or impact the scientific integrity of the study
  • Ongoing therapeutic anticoagulants (curative and preventive regimen) started twenty four (24) hours or more before blood draw (except aspirin and platelet inhibitors)
  • Previous anticoagulant therapy stopped less than three (3) months before blood draw (except aspirin and platelet inhibitors)
  • Patients presenting with a suspect thrombotic event related to catheter implantation
  • Suspect thrombotic events in other locations at screening, including distal to the knee and upper extremity DVT (based on standard of care examinations)
  • Patients with known tissue plasminogen activator (tPA) deficiency
  • Patient participating or who has participated within one month of enrolment in another investigational study

Helyszínek itt: Egyesült Államok

Még 4 másik országban, 8 helyszínen

  • Lehigh HospitalAllentown, Egyesült Államok
  • St. Luke's University Health NetworkBethlehem, Egyesült Államok
  • Massachusetts General HospitalBoston, Egyesült Államok
  • Taylor Regional HospitalCampbellsville, Egyesült Államok
  • Northwestern Medical CenterChicago, Egyesült Államok
  • Ohio State UniversityColumbus, Egyesült Államok
  • UT SouthwesternDallas, Egyesült Államok
  • Duke Hemostasis and Thrombosis Research CenterDurham, Egyesült Államok
  • Indiana University HealthIndianapolis, Egyesült Államok
  • Yale New Haven HospitalNew Haven, Egyesült Államok
  • Jefferson University HospitalPhiladelphia, Egyesült Államok
  • Washington UniversitySt Louis, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Primary objective: To demonstrate the ability of STA® - Liatest® D-Di XL combined with a clinical PreTest Probability (PTP) to safely exclude pulmonary embolism (PE) and deep venous thrombosis (DVT) as measured by Negative Predictive Value (NPV) and sensitivity.

A teljes eredeti leírásKevesebb

Secondary objectives:

1. To estimate additional STA® - Liatest® D-Di XL accuracy parameters, including specificity and positive predictive value (PPV) 2. To constitute a plasma bank to be used for future studies with other DDi assays under development by Stago.

A vizsgálat 2 csoportja

  • Pulmonary Embolism (PE)

    Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development. Enrolment completed for this group : 13th February 2020

    Kezelés: DDimer test

  • Deep Venous Thrombosis (DVT)

    Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development. Enrolment completed for this group : 29th March 2023

    Kezelés: DDimer test

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2025. február 25.